Early program experience in the United States with four-month rifapentine and moxifloxacin–based TB treatment

In 2020, a multicountry phase III randomized controlled clinical trial demonstrated the efficacy and safety of a 4-month regimen composed of isoniazid, rifapentine, moxifloxacin, and pyrazinamide (HPMZ) for the treatment of drug-sensitive TB.